Navigation Links
Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
Date:8/14/2008

entered a Sale and Purchase

Agreement with Tianshi International Investment Group Co., Ltd. (''Tianshi

Investment''). Pursuant to the Sale and Purchase Agreement, Tianshi

Holdings agreed to buy all of the registered share capital of Tianjin

Tiens Life Resources Co., Ltd. (''Life Resources'') for $64.2 million.

The closing of the transaction was subject to government approval of

Transfer of all of the share capital of Life Resources to Tianshi Holdings.

On March 13, 2008, the Chinese government approved the transfer. As

Tianshi Holdings and Life Resources were under common control by Jinyuan

Li before the combination, the combination was treated for accounting

purposes as a pooling of interests. The balance sheet of the Company at

December 31, 2007 and comparative interim financial statements for the

corresponding periods of the preceding fiscal year were adjusted as if

Life Resources had been combined before January 1, 2007. TIENS BIOTECH GROUP (USA), INC. AND SUBSIDIARIES REVENUE BY REGION (Unaudited)

Three months

ended June 30,

2008 2007 Change

China $ 8,509,932 $5,137,313 65.6 %

International $11,144,515 $9,183,169 21.4 %

Total $19,654,447 $14,320,482 37.2 %

Six months

ended June 30,

2008 2007 Change

China $14,615,711 $12,347,614 18.4 %

International $17,859,557 $18,209,657 -1.9 %

Total $32,475,268 $30,557,271 6.3 %
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
2. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
3. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
4. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Yongye Biotechnology International Retains CCG Investor Relations
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
10. Ortho Biotech Announces Nationwide Voluntary Recall of Procrit(R) (Epoetin Alfa) Lot Number P114942A
11. New Book on the Business of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... BRANFORD, Conn., May 21, 2012  HistoRx, the leader ... proprietary AQUA technology to assessment of messenger RNA ... standardization of protein in tissue specimens; this new ... analysis to quantification of nucleic acids.  ...
... PANAMA CITY, Panama, May 21, 2012 International ... 2012 to discuss the potential use of Oxitec,s genetically modified ... Dengue Fever in Panama. The independent forum was ... Memorial Institute for Health Studies and the University of Panama. ...
... 2012  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... the World Stem Cells & Regenerative Medicine Congress ... 22nd at 12:30 PM. Mr. Garr,s presentation, "Stem ... cellular therapy trial in ALS, its neurogenic small ...
Cached Biology Technology:AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 2AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... have added one more trick to the amazing repertoire ... signals to nerve cells. , Nanotubes, tiny hollow carbon ... hair, are already famed as one of the most ... as steel and one-sixth as dense, able to conduct ...
... 2006 is shaping up as the worst year for California's ... of evolution and ecology at UC Davis. , That's a ... migrated through the Central Valley. But other species have seen ... region altogether. , "It has been the worst spring for ...
... used in Chinese medicine to treat the symptoms of ... reverses some of the pancreatic dysfunctions that underlie the ... Metabolism. The chemical therefore represents a useful starting point ... drug could offer a big advance, the group added, ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Where have all the butterflies gone? 2Gardenia fruit compound starting point for diabetes therapy 2
Anti-Mouse Ly 6C.2 , Ascites (Clone 5075-3.6) (mouse IgG2b)...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
PKC (pSer345), phospho-specific...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Biology Products: